Slavomíra Kováčová
Multiple sclerosis (MS) is chronic autoimmune inflammatory and degenerative disorder of the central nervous system
with probably multifactorial ethology which mostly affect young people around age of 30 and represents most common
cause of invalidity in young adults. Natural history studies have shown disability accumulation in nontreated patients
over 10-20 years. Diagnostic and therapeutic options have extended in the past 20 years as well as therapeutic
strategies. The early treatment of first episode of neurologic symptoms (clinically isolated syndrome – CIS) is essential,
subsequent continuous identification of non responders to immunomodulatory drugs and appropriate switch, and ideally
achieve clinical and radiological remission of disease.